CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Hinova Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Hinova Pharmaceuticals Inc
No. 2 and 3, 4F, Building 1
Rongyao Mansion, No. 5, Keyuan South Ro
Phone: +86 2885058465p:+86 2885058465 CHENGDU, SIC  610041  China Ticker: 688302688302
Business Summary
Hinova Pharmaceuticals Inc is a China-based company primarily engaged in the research, development, production and commercialization of innovative drugs. The Company’s main products include the androgen receptor (AR) inhibitor deuterenzalutamide soft capsules (HC-1119), the oral protein degradation-targeting chimeric (PROTAC) drug HP518, the thyroid hormone ß-receptor agonist (THR-ß) agonist HP515, the urate transporter 1 inhibitor (URAT1) inhibitor HP501, the oral PROTAC drug HP568 and the bromodomain and extra terminal domain (BET) inhibitor HP560. The Company's drugs are primarily used to treat cancers such as prostate cancer, breast cancer and hematologic malignancies, as well as metabolic diseases such as hyperuricemia, non-alcoholic steatohepatitis (MASH), obesity and diabetes.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202512/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, General Manager YuanweiChen 62 6/1/2013 6/1/2013
Senior Vice President - Pharmacy WuDu
Senior Vice President - Pharmacy LeiFan
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 173 (As of 12/31/2024)
Outstanding Shares: 99,015,598 (As of 10/13/2025)
Shareholders: 3,352
Stock Exchange: SHA
Fax Number: +86 2885058465


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, February 3, 2026